{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:04:45Z","timestamp":1793747085615,"version":"4.6.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10620-025-09344-w","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T15:50:03Z","timestamp":1755618603000},"page":"3476-3484","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Glucagon-Like Peptide-1 Receptor Agonist Therapy Does Not Increase Gastrointestinal Adverse Events in Patients with Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4051-4722","authenticated-orcid":false,"given":"Jonathan","family":"Weng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5650-3393","authenticated-orcid":false,"given":"Madeline","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2720-4404","authenticated-orcid":false,"given":"Sonia","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"9344_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s13679-023-00506-3","volume":"12","author":"K Arvanitakis","year":"2023","unstructured":"Arvanitakis K, Koufakis T, Popovic D et al. GLP-1 Receptor Agonists in Obese Patients with Inflammatory Bowel Disease: from Molecular Mechanisms to Clinical Considerations and Practical Recommendations for Safe and Effective Use. Curr Obes Rep. 2023;12:61\u201374. https:\/\/doi.org\/10.1007\/s13679-023-00506-3.","journal-title":"Curr Obes Rep."},{"key":"9344_CR2","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrgastro.2016.181","volume":"14","author":"S Singh","year":"2017","unstructured":"Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017;14:110\u2013121. https:\/\/doi.org\/10.1038\/nrgastro.2016.181.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"9344_CR3","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1007\/s10620-015-3629-5","volume":"60","author":"A Flores","year":"2015","unstructured":"Flores A, Burstein E, Cipher DJ, Feagins LA. Obesity in Inflammatory Bowel Disease: A Marker of Less Severe Disease. Dig Dis Sci 2015;60:2436\u20132445. https:\/\/doi.org\/10.1007\/s10620-015-3629-5.","journal-title":"Dig Dis Sci"},{"key":"9344_CR4","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1097\/MIB.0000000000000498","volume":"21","author":"PL Pringle","year":"2015","unstructured":"Pringle PL, Stewart KO, Peloquin JM et al. Body Mass Index, Genetic Susceptibility, and Risk of Complications Among Individuals with Crohn\u2019s Disease. Inflamm Bowel Dis. 2015;21:2304\u20132310. https:\/\/doi.org\/10.1097\/MIB.0000000000000498.","journal-title":"Inflamm Bowel Dis."},{"key":"9344_CR5","doi-asserted-by":"publisher","first-page":"e241","DOI":"10.1016\/j.crohns.2012.09.009","volume":"7","author":"T Nic Suibhne","year":"2013","unstructured":"Nic Suibhne T, Raftery TC, McMahon O, Walsh C, O\u2019Morain C, O\u2019Sullivan M. High prevalence of overweight and obesity in adults with Crohn\u2019s disease: associations with disease and lifestyle factors. J Crohns Colitis. 2013;7:e241\u2013e248. https:\/\/doi.org\/10.1016\/j.crohns.2012.09.009.","journal-title":"J Crohns Colitis."},{"key":"9344_CR6","doi-asserted-by":"publisher","first-page":"C375","DOI":"10.1152\/ajpcell.00379.2020","volume":"320","author":"T Kawai","year":"2021","unstructured":"Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol 2021;320:C375\u2013C391. https:\/\/doi.org\/10.1152\/ajpcell.00379.2020.","journal-title":"Am J Physiol Cell Physiol"},{"key":"9344_CR7","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1007\/s10620-024-08504-8","volume":"69","author":"M Mahmoud","year":"2024","unstructured":"Mahmoud M, Syn WK. Impact of Obesity and Metabolic Syndrome on IBD Outcomes. Dig Dis Sci 2024;69:2741\u20132753. https:\/\/doi.org\/10.1007\/s10620-024-08504-8.","journal-title":"Dig Dis Sci"},{"key":"9344_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.metabol.2013.09.010","volume":"63","author":"YS Lee","year":"2014","unstructured":"Lee YS, Jun HS. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism 2014;63:9\u201319. https:\/\/doi.org\/10.1016\/j.metabol.2013.09.010.","journal-title":"Metabolism"},{"key":"9344_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s13300-011-0002-3","volume":"2","author":"C Koliaki","year":"2011","unstructured":"Koliaki C, Doupis J. Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Ther 2011;2:101\u2013121. https:\/\/doi.org\/10.1007\/s13300-011-0002-3.","journal-title":"Diabetes Ther"},{"key":"9344_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11154-014-9289-5","volume":"15","author":"M Shah","year":"2014","unstructured":"Shah M, Vella A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord 2014;15:181\u2013187. https:\/\/doi.org\/10.1007\/s11154-014-9289-5.","journal-title":"Rev Endocr Metab Disord"},{"key":"9344_CR11","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00210-019-01698-z","volume":"392","author":"H Zatorski","year":"2019","unstructured":"Zatorski H, Salaga M, Fichna J. Role of glucagon-like peptides in inflammatory bowel diseases-current knowledge and future perspectives. Naunyn Schmiedebergs Arch Pharmacol 2019;392:1321\u20131330. https:\/\/doi.org\/10.1007\/s00210-019-01698-z.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"9344_CR12","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1111\/1440-1681.13361","volume":"47","author":"O Azmy Nabeh","year":"2020","unstructured":"Azmy Nabeh O, Ishak Attallah M, El-Sayed El-Gawhary N. The pivotal relation between glucagon-like peptides, NFkappaB and inflammatory bowel disease. Clin Exp Pharmacol Physiol. 2020;47:1641\u20131648. https:\/\/doi.org\/10.1111\/1440-1681.13361.","journal-title":"Clin Exp Pharmacol Physiol."},{"key":"9344_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/JIR.S152835","volume":"11","author":"A Al-Dwairi","year":"2018","unstructured":"Al-Dwairi A, Alqudah TE, Al-Shboul O, Alqudah M, Mustafa AG, Alfaqih MA. Glucagon-like peptide-1 exerts anti-inflammatory effects on mouse colon smooth muscle cells through the cyclic adenosine monophosphate\/nuclear factor-kappaB pathway in vitro. J Inflamm Res 2018;11:95\u2013109. https:\/\/doi.org\/10.2147\/JIR.S152835.","journal-title":"J Inflamm Res"},{"key":"9344_CR14","doi-asserted-by":"publisher","unstructured":"Hunt JE, Holst JJ, Jeppesen PB, Kissow H. 2021 GLP-1 and Intestinal Diseases. Biomedicines. 9(4). https:\/\/doi.org\/10.3390\/biomedicines9040383","DOI":"10.3390\/biomedicines9040383"},{"key":"9344_CR15","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1080\/003655200750023796","volume":"35","author":"PT Schmidt","year":"2000","unstructured":"Schmidt PT, Hartmann B, Bregenholt S, Hoist JJ, Claesson MH. Deficiency of the intestinal growth factor, glucagon-like peptide 2, in the colon of SCID mice with inflammatory bowel disease induced by transplantation of CD4+ T cells. Scand J Gastroenterol 2000;35:522\u2013527. https:\/\/doi.org\/10.1080\/003655200750023796.","journal-title":"Scand J Gastroenterol"},{"key":"9344_CR16","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.2337\/db14-1577","volume":"64","author":"B Yusta","year":"2015","unstructured":"Yusta B, Baggio LL, Koehler J et al. GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R. Diabetes 2015;64:2537\u20132549. https:\/\/doi.org\/10.2337\/db14-1577.","journal-title":"Diabetes"},{"key":"9344_CR17","doi-asserted-by":"publisher","first-page":"1043789","DOI":"10.3389\/fendo.2022.1043789","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne) 2022;13:1043789. https:\/\/doi.org\/10.3389\/fendo.2022.1043789.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"9344_CR18","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/cpt.2430","volume":"111","author":"JL Faillie","year":"2022","unstructured":"Faillie JL, Yin H, Yu OHY et al. Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes. Clin Pharmacol Ther. 2022;111:272\u2013282. https:\/\/doi.org\/10.1002\/cpt.2430.","journal-title":"Clin Pharmacol Ther."},{"key":"9344_CR19","doi-asserted-by":"publisher","unstructured":"Weiss T, Yang L, Carr RD, et al. 2022 Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK. BMJ Open Diabetes Res Care 10(1). https:\/\/doi.org\/10.1136\/bmjdrc-2021-002517","DOI":"10.1136\/bmjdrc-2021-002517"},{"key":"9344_CR20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","volume":"11","author":"TD Filippatos","year":"2014","unstructured":"Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse Effects of GLP-1 Receptor Agonists. Rev Diabet Stud. Fall-Winter 2014;11:202\u2013230. https:\/\/doi.org\/10.1900\/RDS.2014.11.202.","journal-title":"Rev Diabet Stud. Fall-Winter"},{"key":"9344_CR21","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s40261-022-01202-1","volume":"42","author":"T Wu","year":"2022","unstructured":"Wu T, Zhang Y, Shi Y et al. Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database. Clin Drug Investig. 2022;42:965\u2013975. https:\/\/doi.org\/10.1007\/s40261-022-01202-1.","journal-title":"Clin Drug Investig."},{"key":"9344_CR22","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.therap.2020.02.024","volume":"75","author":"B Gudin","year":"2020","unstructured":"Gudin B, Ladhari C, Robin P et al. Incretin-based drugs and intestinal obstruction: A pharmacovigilance study. Therapie 2020;75:641\u2013647. https:\/\/doi.org\/10.1016\/j.therap.2020.02.024.","journal-title":"Therapie"},{"key":"9344_CR23","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1001\/jama.2023.19574","volume":"330","author":"M Sodhi","year":"2023","unstructured":"Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023;330:1795\u20131797. https:\/\/doi.org\/10.1001\/jama.2023.19574.","journal-title":"JAMA."},{"key":"9344_CR24","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.cgh.2023.08.034","volume":"22","author":"P Ueda","year":"2024","unstructured":"Ueda P, Wintzell V, Melbye M et al. Use of DPP4 Inhibitors and GLP-1 Receptor Agonists and Risk of Intestinal Obstruction: Scandinavian Cohort Study. Clin Gastroenterol Hepatol. 2024;22:1226-1237 e14. https:\/\/doi.org\/10.1016\/j.cgh.2023.08.034.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9344_CR25","doi-asserted-by":"publisher","unstructured":"Alfehaid L, Alyami M, Almohareb S, Alshaya O, Almutairi A. 2025 Evaluating bowel obstruction and ileus events in patients on GLP-1 receptor agonists: a systematic review and meta-analysis. Expert Opin Drug Saf 1\u20139. https:\/\/doi.org\/10.1080\/14740338.2025.2465870","DOI":"10.1080\/14740338.2025.2465870"},{"key":"9344_CR26","doi-asserted-by":"publisher","unstructured":"Popoviciu MS, Paduraru L, Yahya G, Metwally K, Cavalu S. 2023 Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. Int J Mol Sci 24(13). https:\/\/doi.org\/10.3390\/ijms241310449","DOI":"10.3390\/ijms241310449"},{"key":"9344_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae276","author":"J Nielsen","year":"2024","unstructured":"Nielsen J, Friedman S, Norgard BM, Knudsen T, Kjeldsen J, Wod M. Glucagon-Like Peptide 1 Receptor Agonists Are Not Associated With an Increased Risk of Ileus or Intestinal Obstruction in Patients with Inflammatory Bowel Disease-A Danish Nationwide Cohort Study. Inflamm Bowel Dis. 2024. https:\/\/doi.org\/10.1093\/ibd\/izae276.","journal-title":"Inflamm Bowel Dis"},{"key":"9344_CR28","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/ibd\/izae250","volume":"31","author":"I Levine","year":"2025","unstructured":"Levine I, Sekhri S, Schreiber-Stainthorp W et al. GLP-1 Receptor Agonists Confer No Increased Rates of IBD Exacerbation Among Patients With IBD. Inflamm Bowel Dis. 2025;31:467\u2013475. https:\/\/doi.org\/10.1093\/ibd\/izae250.","journal-title":"Inflamm Bowel Dis."},{"key":"9344_CR29","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003208","author":"SR Anderson","year":"2024","unstructured":"Anderson SR, Ayoub M, Coats S, McHenry S, Tan T, Deepak P. Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease. Am J Gastroenterol. 2024. https:\/\/doi.org\/10.14309\/ajg.0000000000003208.","journal-title":"Am J Gastroenterol"},{"key":"9344_CR30","doi-asserted-by":"publisher","first-page":"100979","DOI":"10.1016\/j.eclinm.2021.100979","volume":"37","author":"M Villumsen","year":"2021","unstructured":"Villumsen M, Schelde AB, Jimenez-Solem E, Jess T, Allin KH. GLP-1 based therapies and disease course of inflammatory bowel disease. EClinicalMedicine. 2021;37:100979. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100979.","journal-title":"EClinicalMedicine."},{"key":"9344_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03412-w","author":"Y Xie","year":"2025","unstructured":"Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-024-03412-w.","journal-title":"Nat Med"},{"key":"9344_CR32","doi-asserted-by":"publisher","unstructured":"Lourie J. 2019 A Novel Use of Liraglutide: Induction of Partial Remission in Ulcerative Colitis and Ankylosing Spondylitis. Clinical Medical Reviews and Case Reports. 6(8). https:\/\/doi.org\/10.23937\/2378-3656\/1410281","DOI":"10.23937\/2378-3656\/1410281"},{"key":"9344_CR33","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160:1570\u20131583. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.031.","journal-title":"Gastroenterology."},{"key":"9344_CR34","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.suc.2019.08.007","volume":"99","author":"RN Goldstone","year":"2019","unstructured":"Goldstone RN, Steinhagen RM. Abdominal Emergencies in Inflammatory Bowel Disease. Surg Clin North Am 2019;99:1141\u20131150. https:\/\/doi.org\/10.1016\/j.suc.2019.08.007.","journal-title":"Surg Clin North Am"},{"key":"9344_CR35","doi-asserted-by":"publisher","first-page":"103414","DOI":"10.1016\/j.jaut.2025.103414","volume":"153","author":"Y Yang","year":"2025","unstructured":"Yang Y, Liu W, Zhang Z et al. Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agents in autoimmune diseases. J Autoimmun 2025;153:103414. https:\/\/doi.org\/10.1016\/j.jaut.2025.103414.","journal-title":"J Autoimmun"},{"key":"9344_CR36","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Frias","year":"2021","unstructured":"Frias JP, Davies MJ, Rosenstock J et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021;385:503\u2013515. https:\/\/doi.org\/10.1056\/NEJMoa2107519.","journal-title":"N Engl J Med"},{"key":"9344_CR37","doi-asserted-by":"publisher","unstructured":"Gorgojo-Martinez JJ, Mezquita-Raya P, Carretero-Gomez J, et al. 2022 Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J Clin Med. 12(1). https:\/\/doi.org\/10.3390\/jcm12010145","DOI":"10.3390\/jcm12010145"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09344-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-09344-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09344-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:45:12Z","timestamp":1762872312000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-09344-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["9344"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-09344-w","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests related to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}